Neuronal Nicotinic Receptor

Acronym

Definition

nAChR

Neuronal Nicotinic Acetylcholine Receptor

nAChR

Neuronal Nicotinic Receptor

NACHR

National Association of Healthcare Recruiters (Morrisville, NC)

References in periodicals archive	?		Acronyms browser	?		Full browser	?
This study provides the first substantive clinical evidence that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties," said Dr. Drug's efficacy for treating depression 'exciting' by Jancin, Bruce / Clinical Psychiatry News a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), has initiated a Phase I clinical trial of TC-5619, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7. TARGACEPT INITIATES PHASE I CLINICAL TRIAL OF TC-5619 by Biotech Business a clinical-stage biopharmaceutical company focused on a new class of drugs that selectively target neuronal nicotinic receptors, or NNRs, to treat central nervous system diseases and disorders today reported its financial results for the first quarter ended March 31, 2006. TARGACEPT REPORTS NET LOSS OF 5.5 MIL FOR FIRST QTR 2006 by Biotech Financial Reports	NETWIB NETWORK NetWoRM NETZINE NEU NEUA NEUC NEUD NEUDC NEUF NEUFIE NEUFODI NEUI NEUL NEUM NEUPG NEUQ NEUR neurelitism NEURO- NEUROBOT NEUROCOLT NEUROD NEUROD1 NEURON Neuronal Nicotinic Receptor NEURONET NEUROQUACS NEURS NEUS NEUST NEUT NEUTRA NEUTRABAS NEUYM NEV NEVA NEVAC NEVACC NEVADA NEVB NEVBA NEVC NEVCA NEVCC NEVCO NEVD NEVDGP NEVDIS NEVE NEVES	Neuronal Ceroid Lipofuscinoses Research Alliance Neuronal ceroid lipofuscinosis Neuronal ceroid lipofuscinosis Neuronal Ceroid-Lipofuscinosis Neuronal Ceroid-Lipofuscinosis Neuronal Conditioned Medium neuronal gap junctions neuronal glycoproteinosis neuronal glycoproteinosis Neuronal Group Selection Theory neuronal heterotopia neuronal heterotopia neuronal inclusion-body disease neuronal inclusion-body disease neuronal interface Neuronal Intermediate Filament Inclusion Disease Neuronal intestinal dysplasia Neuronal Intestinal Dysplasia Type B Neuronal Intranuclear Inclusion Disease Neuronal KappaB-Binding Factor Neuronal Kinesin Heavy Chain Neuronal Leucine-Rich Repeat neuronal lipodystrophy neuronal lipodystrophy Neuronal loss Neuronal loss Neuronal loss Neuronal Network Model Neuronal Nicotinic Acetylcholine Receptor Neuronal Nicotinic Acetylcholine Receptor Alpha 4 Subunit Neuronal Nicotinic Receptor Neuronal Nitric Oxide Synthase Neuronal Nitric Oxide Synthase Neuronal Nitric-Oxide Synthase 2 Neuronal Nuclear Volume Neuronal Pentraxin 1 Neuronal Pentraxin 2 Neuronal Phase-Locked Loop neuronal plasticity neuronal processes neuronal processes Neuronal Protein of 185 Kilodaltons neuronal sprouting Neuronal Thread Protein Neuronal Thread Protein-Like Immunoreactivity Neuronal Type Nitric Oxide Synthase neuronal vacuolar degeneration neuronal vacuolar degeneration Neuronal Voltage-Dependent Sodium Channel Neuronal Wiskott-Aldrich Syndrome Protein neuronally neuronally neuronally Neuronally Expressed EPH-Related Tyrosine Kinase neurone neurone neurone Neurones Neurones Neurones NEURONET

References in periodicals archive

Acronyms browser

Full browser

This study provides the first substantive clinical evidence that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties," said Dr.

Drug's efficacy for treating depression 'exciting' by Jancin, Bruce / Clinical Psychiatry News

a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), has initiated a Phase I clinical trial of TC-5619, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7.

TARGACEPT INITIATES PHASE I CLINICAL TRIAL OF TC-5619 by Biotech Business

a clinical-stage biopharmaceutical company focused on a new class of drugs that selectively target neuronal nicotinic receptors, or NNRs, to treat central nervous system diseases and disorders today reported its financial results for the first quarter ended March 31, 2006.

TARGACEPT REPORTS NET LOSS OF 5.5 MIL FOR FIRST QTR 2006 by Biotech Financial Reports